Indivior PLC (NASDAQ:INDV) Sees Significant Growth in Short Interest

Indivior PLC (NASDAQ:INDV - Get Free Report) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 2,060,000 shares, a growth of 68.9% from the February 13th total of 1,220,000 shares. Currently, 1.9% of the company's stock are sold short. Based on an average daily volume of 1,440,000 shares, the days-to-cover ratio is currently 1.4 days.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on INDV shares. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a research note on Tuesday, January 28th. Rodman & Renshaw initiated coverage on Indivior in a report on Tuesday, January 28th. They set a "buy" rating and a $16.00 price target for the company. Finally, Piper Sandler decreased their price target on Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a report on Thursday, March 6th.

Indivior Stock Performance

NASDAQ INDV traded up $0.21 during trading on Wednesday, reaching $9.95. 1,426,078 shares of the company's stock were exchanged, compared to its average volume of 621,448. The stock has a market cap of $1.37 billion, a P/E ratio of -28.43 and a beta of 0.82. The company has a 50 day moving average price of $10.50 and a two-hundred day moving average price of $10.44. Indivior has a 1 year low of $7.33 and a 1 year high of $22.53.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.32. The company had revenue of $298.00 million during the quarter, compared to the consensus estimate of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. Research analysts forecast that Indivior will post 1.22 EPS for the current fiscal year.

Remove Ads

Institutional Trading of Indivior

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rathbones Group PLC lifted its holdings in shares of Indivior by 11.6% in the 4th quarter. Rathbones Group PLC now owns 14,284 shares of the company's stock valued at $183,000 after purchasing an additional 1,483 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Indivior by 4.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,327 shares of the company's stock valued at $408,000 after purchasing an additional 1,888 shares during the last quarter. Two Sigma Investments LP lifted its holdings in shares of Indivior by 2.1% in the 4th quarter. Two Sigma Investments LP now owns 110,880 shares of the company's stock valued at $1,378,000 after purchasing an additional 2,237 shares during the last quarter. Stifel Financial Corp lifted its holdings in shares of Indivior by 24.0% in the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company's stock valued at $158,000 after purchasing an additional 2,450 shares during the last quarter. Finally, PDT Partners LLC lifted its holdings in shares of Indivior by 4.7% in the 4th quarter. PDT Partners LLC now owns 57,520 shares of the company's stock valued at $715,000 after purchasing an additional 2,596 shares during the last quarter. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.